Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Zenapax or Simulect for depletion of regulatory T-lymphocytes in metastatic cancer
2005-003997-74Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of daclizumab and basiliximab in cancer (2 arms), sponsored by Rigshospitalet. Started Jan 2006; status: completed.
02
Drugs
daclizumabbasiliximab
03
Conditions
cancer
Beyond the preview
Go deeper on 2005-003997-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003997-74.